CD19 and COVID-19: Anti‐CD19 antibody monotherapy (Inebilizumab) also produced similar outcomes to COVID‐19, since antibody generation and responses to COVID‐19 vaccinations were hampered when treated with B‐cell‐depleting therapies.27